Glenmark Pharmaceuticals (GLENMARK) — Announcement

📢 Key Event
Glenmark secures U.S. FDA approval for generic Flonase nasal spray

💡 Investor Takeaway
The approval opens a $295 million U.S. market opportunity for Glenmark's respiratory portfolio, potentially boosting future revenue and shareholder value.

Glenmark Pharmaceuticals announced U.S. FDA approval for its generic Fluticasone Propionate Nasal Spray, bioequivalent to GlaxoSmithKline's Flonase, targeting the $295.2 million U.S. nasal spray market. The approval enables commercial launch in the U.S. via Glenmark Pharmaceuticals Inc., expanding its respiratory portfolio and revenue potential in a high-growth therapeutic area.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLENMARK ✨ Ask AI About This

About Glenmark Pharmaceuticals Limited (GLENMARK)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹68,205.11 Cr P/E: 37.9 ROE: 20.3% ROCE: 24.8% Div Yield: 0.10%

View full GLENMARK stock details →

📡 Get AI alerts when GLENMARK files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLENMARK — Free

💡 Ask AI about this filing

"How will Glenmark capture market share in the $295M U.S. Flonase generic market?" "What pricing strategy will Glenmark use for its approved nasal spray?" "When will Glenmark launch the product commercially in the U.S.?"

Ask AI Free →

📊 More GLENMARK filings

See all GLENMARK filings →

🔥 Also filed on 20 August 2026

JSLL Jeena Sikho Lifecare Limited Financial Results ANURAS Anupam Rasayan India Limited Financial Results NIRAJ Niraj Cement Structurals Limited Announcement PNBHOUSING PNB Housing Finance Limited Corporate Action KRONOX Kronox Lab Sciences Limited Announcement SUPRAJIT Suprajit Engineering Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLENMARK files new disclosures

Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLENMARK — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd